Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
| Status: | Archived |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2007 |
| End Date: | October 2010 |
The goal of this project is to investigate the effects that the addition of aldosterone
blockade with eplerenone will have on the progression of diastolic dysfunction in patients
with controlled essential hypertension.
The purpose of this project is to determine if eplerenone, an aldosterone blocker, prevents
remodelling of the heart in patients with controlled essential hypertension, defined as
having a blood pressure of equal to or less than 130/80 in diabetics and equal to or less
than 140/90 in non-diabetics. This study will investigate if the addition of 25 milligrams
of eplerenone daily to a subject's hypertension medication regimen will prevent the
progression or development of diastolic dysfunction. Echocardiography will be used to
measure the changes in heart structure of subjects receiving eplerenone versus subjects
receiving placebo (a drug that may resemble the study drug but contains no active
ingredient). Approximately 30 subjects will take part in this study.
We found this trial at
1
site
Creighton University Creighton University, located in Omaha, Neb., offers a top-ranked education in the Jesuit...
Click here to add this to my saved trials
